A detailed history of Bank Of America Corp transactions in Cassava Sciences Inc stock. As of the latest transaction made, Bank Of America Corp holds 120,591 shares of SAVA stock, worth $3.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
120,591
Previous 143,905 16.2%
Holding current value
$3.25 Million
Previous $2.92 Million 48.99%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$12.35 - $26.11 $287,927 - $608,728
-23,314 Reduced 16.2%
120,591 $1.49 Million
Q1 2024

May 15, 2024

SELL
$18.44 - $26.41 $1.66 Million - $2.38 Million
-90,036 Reduced 38.49%
143,905 $2.92 Million
Q4 2023

Feb 14, 2024

BUY
$12.64 - $30.11 $761,319 - $1.81 Million
60,231 Added 34.67%
233,941 $5.27 Million
Q2 2023

Aug 14, 2023

SELL
$21.59 - $27.88 $972,823 - $1.26 Million
-45,059 Reduced 20.6%
173,710 $4.26 Million
Q1 2023

May 12, 2023

BUY
$23.46 - $36.44 $2.76 Million - $4.29 Million
117,742 Added 116.55%
218,769 $5.28 Million
Q4 2022

Feb 10, 2023

SELL
$27.82 - $44.16 $4.59 Million - $7.29 Million
-164,973 Reduced 62.02%
101,027 $2.98 Million
Q3 2022

Nov 14, 2022

BUY
$16.33 - $51.06 $2.02 Million - $6.31 Million
123,547 Added 86.73%
266,000 $11.1 Million
Q2 2022

Aug 12, 2022

BUY
$17.22 - $38.47 $1.94 Million - $4.34 Million
112,808 Added 380.53%
142,453 $4.01 Million
Q1 2022

May 16, 2022

SELL
$32.6 - $53.05 $8 Million - $13 Million
-245,462 Reduced 89.22%
29,645 $1.1 Million
Q4 2021

Feb 08, 2022

BUY
$36.77 - $90.91 $4.54 Million - $11.2 Million
123,437 Added 81.39%
275,107 $12 Million
Q3 2021

Nov 15, 2021

BUY
$41.79 - $135.3 $5.32 Million - $17.2 Million
127,274 Added 521.7%
151,670 $9.42 Million
Q2 2021

Sep 13, 2021

BUY
$32.15 - $89.72 $784,331 - $2.19 Million
24,396 New
24,396 $2.09 Million

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.08B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.